ProMIS Neurosciences Inc. PMN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-76.7
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$39.7M | — | — | -$1.3M |
| 2024 | — | $2.8M | — | — | $16.5M |
| 2023 | — | -$13.2M | — | — | $3.8M |
| 2022 | — | -$18.1M | — | -$17.0M | -$1.3M |
| 2021 | — | -$9.8M | — | -$9.3M | $5.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Kirwin Patrick D. | director | 2026-04-22 | Buy | 4,000 | $11.33 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -76.7 (distress)
- Working capital / assets -0.134
- Retained earnings / assets -14.202
- EBIT / assets -4.374
- Equity / liabilities -0.121
Source: SEC EDGAR filings · CIK 0001374339 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.